 Home > Active Ingredient News > Antitumor Therapy > Kangfang Bio-PD1 monoclonal antibody obtained FDA breakthrough therapy qualification, third-line treatment of metastatic nasopharyngeal carcinoma

Kangfang Bio-PD1 monoclonal antibody obtained FDA breakthrough therapy qualification, third-line treatment of metastatic nasopharyngeal carcinoma

 Last Update: 2021-04-13
 Source: Internet
 Author: User

Tags

her2 gastric cancer

thp 1 cell line

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On March 30, Kangfang Biological announced that the FDA granted Paimrizumab breakthrough therapy qualification for the third-line treatment of metastatic nasopharyngeal carcinoma.

Kangfang Bio-Bio announced in September 2020 that the registered clinical trial of Paimrizumab for the third-line treatment of metastatic nasopharyngeal carcinoma has reached the primary endpoint of objective response rate (ORR) assessed by independent imaging, and has undergone multi-line treatment in the past.

Nasopharyngeal carcinoma is a malignant tumor that occurs in the mucosal epithelium of the nasopharyngeal area, and mostly occurs in the top and side walls of the nasopharynx.

Paimrizumab was jointly developed and commercialized by Kangfang Biotechnology and Chia Tai Tianqing.

In May 2020, Kangfang Bio-Bio submitted to NMPA a new drug listing application for Paimrizumab to treat relapsed or refractory classic Hodgkin's lymphoma (r/rcHL) after at least second-line system chemotherapy.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Kangfang Bio-PD1 monoclonal antibody obtained FDA breakthrough therapy qualification for third-line treatment of metastatic nasopharyngeal carcinoma

04-14

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Kangfang Bio-PD1 monoclonal antibody obtained FDA breakthrough therapy qualification, third-line treatment of metastatic nasopharyngeal carcinoma

Related Articles

Kangfang Bio-PD1 monoclonal antibody obtained FDA breakthrough therapy qualification for third-line treatment of metastatic nasopharyngeal carcinoma